The anti-obesity drug market comprises drugs that help in weight loss and weight management by decreasing appetite or increasing feelings of fullness. Obesity drugs aim to help obese and overweight individuals lose weight and sustain weight loss by regulating appetite and enhancing satiety. Some common anti-obesity medications include Phentermine, Orlistat, Lorcaserin, etc. These drugs are prescribed along with exercise and a reduced-calorie diet for effective weight management. The global anti-obesity drug market is estimated to be valued at US$ 2542 Mn in 2023 and is expected to exhibit a CAGR of 7.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics: The anti-obesity drug market is expected to witness significant growth over the forecast period owing to the growing prevalence of obesity worldwide due to sedentary lifestyles and consumption of junk food. It is estimated that nearly 2.8 million people die each year worldwide as a result of being overweight or obese. Moreover, obesity increases the risk of various chronic diseases like diabetes, cardiovascular diseases, musculoskeletal disorders, and certain cancers. This has boosted the demand for effective anti-obesity medications for weight loss and management. Furthermore, rising awareness about health and fitness among consumers and availability of new drug formulations are also contributing to growth of the anti-obesity drug market over the forecast period.

SWOT Analysis
Strength: The anti-obesity drug market has high potential for growth due to the rising prevalence of obesity worldwide. With more drug approvals, the availability of effective drugs for weight loss and management is increasing. Continuous research and development activities by key players are leading to innovations in drug formulation and delivery.

Weakness: Adherence to drug regimens can be challenging for patients due to potential side effects of anti-obesity drugs. Safety concerns regarding cardiovascular and neuropsychiatric risks also remain a weakness. High development costs and regulatory hurdles lengthen the time for new drugs to enter the market.

Opportunity: The increasing focus on drug combinations and pipeline drugs targeting new obesity mechanisms provides lucrative opportunities. Digital drug therapies and remote monitoring solutions are opening new avenues. Growing obesity rates in developing regions present a major market opportunity.

Threats: Patent expiries of blockbuster drugs lead to price erosion and competition from generics. Alternative treatment options and lifestyle management practices can threaten drug sales. Stringent regulations and reimbursement policies in some countries pose challenges.

Key Takeaways

The global Anti-Obesity Drug Market Growth is expected to witness high growth over the forecast period of 2023 to 2030 driven by the rising prevalence of obesity worldwide. As per estimates, the market size was valued at US$ 2542 Mn in 2024 and is anticipated to reach over US$ 4500 Mn by 2030, exhibiting a CAGR of around 7.9% during the forecast period.

Regional analysis: North America currently dominates the anti-obesity drug market owing to the rising healthcare costs of obesity. However, the Asia Pacific region is estimated to witness the fastest growth due to improving access to healthcare facilities and growing obesity concerns in densely populated countries like China and India.

Key players: Key players operating in the anti-obesity drug market include ARJO, Etac AB, Medline Industries Inc., Guldmann Inc., Sunrise Medical Inc., Stryker Corporation, Winncare Group (Mangar Health), Joerns Healthcare Inc., Invacare Corporation, Baxter (Hill Rom Holding Inc.), Gainsborough Healthcare Group, and Savaria Corporation (Handicare Group AB), among others. These players are focused on new product development, partnerships and geographical expansion strategies to gain market share.

 For more insights, read-